-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The Center for Drug Evaluation (CDE) of the National Medical Products Administration of China recently announced that Amgen's Class 1 new drug, AMG 570, has obtained a clinical trial implied license to develop the treatment of systemic lupus erythematosus (SLE).
Screenshot source: CDE official website
Systemic lupus erythematosus is a chronic systemic autoimmune disease with clinical manifestations of multiple system damage.
ICOS (also known as CD278) is an immune checkpoint expressed on activated T cells and is a type of co-stimulatory receptor.
BAFF (B cell activating factor), also known as BLyS (B lymphocyte stimulating factor), can support B cell survival by binding to the BAFF receptor (BAFFR) expressed on B cells.
AMG 570 is a bispecific antibody developed by Amgen that can simultaneously target BAFF and ICOSL and is intended to be used to treat diseases such as systemic lupus erythematosus.
Note: The original text has been deleted
▽ attention [drug Mingkang Germany ] micro-channel public number
[Medical attention Mingkang Germany ] ] micro-channel public number
